NCT05380713View on ClinicalTrials.gov

......SMARTEST Trial......

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 3, 2022

Primary Completion Date

July 30, 2025

Study Completion Date

October 30, 2028

Conditions
Mesothelioma, Malignant
Interventions
DRUG

Cyclophosphamide

Cyclophosphamide will be applied in the neoadjuvant setting

DRUG

Tremelimumab

tremelimumab-durvalumab in adjuvant setting

DRUG

Durvalumab

tremelimumab-durvalumab in adjuvant setting

Trial Locations (1)

Unknown

RECRUITING

Princess Margaret Cancer Centre, Toronto

Sponsors
All Listed Sponsors
collaborator

Ontario Institute for Cancer Research

OTHER

lead

University Health Network, Toronto

OTHER